3,4-Diaminopyridine safety in clinical practice: An observational, retrospective cohort study

Journal of Neurology

Volumn 257, Issue 6, 2010, Pages 937-946

  Flet, Laurent ^a   Polard, Elisabeth ^b   Guillard, Olivia ^c   Leray, Emmanuelle ^c   Allain, Hervé ^b   Javaudin, Loïc ^c   Edan, Gilles ^c  

^a HÔTEL DIEU   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Aminopyridines; Drug complications; Drug treatment of MS; MS; Neuromuscular disorders

Indexed keywords

3,4 DIAMINOPYRIDINE; 4 AMINOPYRIDINE; AMANTADINE; MITOXANTRONE; MODAFINIL; 3,4-DIAMINOPYRIDINE; POTASSIUM CHANNEL BLOCKING AGENT;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY DISORDER; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; COLD SENSATION; CONVULSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; EPIGASTRIC PAIN; EPILEPSY; EXCITEMENT; EYE IRRITATION; FATIGUE; FEMALE; FRANCE; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HEPATITIS; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPEREOSINOPHILIA; HYPERTENSION; JOINT STIFFNESS; LIVER BIOPSY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; METEORISM; MOTOR PERFORMANCE; MULTIPLE SCLEROSIS; MUSCLE CRAMP; MUSCLE RIGIDITY; MUSCLE SPASM; MYOTONIC DYSTROPHY; NAUSEA; NERVOUSNESS; OBSERVATIONAL STUDY; PAIN; PARESTHESIA; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SORE THROAT; THORAX PAIN; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN; XEROSTOMIA; ADOLESCENT; ANALOGS AND DERIVATIVES; CHILD; CLINICAL TRIAL; COMPLICATION; DYSKINESIAS; MIDDLE AGED; TIME; TREATMENT OUTCOME; YOUNG ADULT;

4-AMINOPYRIDINE; ADOLESCENT; ADULT; AGED; CHILD; COHORT STUDIES; DYSKINESIAS; FATIGUE; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POTASSIUM CHANNEL BLOCKERS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954425585     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-009-5442-6     Document Type: Article

References (39)

1. ML Aisen D Sevilla L Edelstein J Blass 1996 A double-blind placebo-controlled study of 3,4-diaminopyridine in amytrophic lateral sclerosis patients on a rehabilitation unit J Neurol Sci 138 93 96 10.1016/0022-510X(96) 00012-3 1:STN:280:DyaK28zotlersw%3D%3D 8791245 (Pubitemid 26195860)
2. AG Beiske H Naess JH Aarseth O Andersen I Elovaara M Farkkila HJ Hansen SI Mellgren M Sandberg-Wollheim PS Sorensen KM Myhr 2007 Health-related quality of life in secondary progressive multiple sclerosis Mult Scler 13 386 392 10.1177/13524585070130030101 1:STN:280:DC%2BD2s3jtFGisA%3D%3D 17439908 (Pubitemid 46706000)
3. FW Bertelsmann CH Polman HAM Van Diemen, et al.. 1992 A comparison between 4-aminopyridine and 3,4-diaminopyridine in the treatment of multiple sclerosis Ann Neurol 32 256
4. CT Bever 1994 The current status of studies of aminopyridines in patients with multiple sclerosis Ann Neurol 36 S118 S121 10.1002/ana.410360728 8017870 (Pubitemid 24220857)
5. CT Bever PA Anderson J Leslie HS Panitch S Dhib-Jaibut OA Khan R Milo JR Hebel KL Conway E Katz KP Johnson 1996 Treatment with oral 3,4-diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial Neurology 47 1457 1462 1:CAS:528:DyaK2sXjsFymsQ%3D%3D 8960727 (Pubitemid 26422536)
6. CT Bever J Leslie DL Camenga HS Panitch KP Johnson 1990 Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis Ann Neurol 27 421 427 10.1002/ana.410270411 2353797 (Pubitemid 20132058)
7. Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSaPS) (2005) Bonnes Pratiques de Pharmacovigilance. Available at: http://www.afssaps.fr/Activites/Pharmacovigilance/Textes- reglementaires-de-la-Pharmacovigilance/(offset)/7. Accessed 4 Jan 2010
8. JL Carter JC Stevens B Smith, et al.. 1993 A double-blind, placebo-controlled crossover trial of 3,4-diaminopyridine in the symptomatic treatment of multiple sclerosis Ann Neurol 34 108 10.1002/ana.410340118
9. B Casanova JJ Vilchez P Rubio 1993 The treatment of the Eaton-Lambert myasthenic syndrome with 3,4-diaminopyridine Rev Clin Esp 192 354 355 1:STN:280:DyaK3s3mvFSmsA%3D%3D 8388576 (Pubitemid 23176994)
10. C Confavreux 1994 Establishment and use of multiple sclerosis registers: EDMUS Ann Neurol 36 S136 S139 10.1002/ana.410360733 8017876 (Pubitemid 24220862)
11. C Confavreux DA Compston OR Hommes WI Mc Donald AJ Thompson 1992 EDMUS, a European database for multiple sclerosis J Neurol Neurosurg Psychiatr 55 671 676 10.1136/jnnp.55.8.671 1:STN:280:DyaK38vgslGmsw%3D%3D 1527537
12. Curti C, Feuillet L, Villano P, Pelletier J, Gensollen S, Timon David P, Bongrand MC (2004) Tolerance and efficacy of 3,4-diaminopyridine in patients suffering from multiple sclerosis. In: 2nd American College of Clinical Pharmacy-European Society of Clinical Pharmacy joint meeting, Paris, 28-30 May
13. Demolis JL, Acar V, Raphael M, Goulay-Dufay S, Pradeau D, Funck-Brentano C (2005) Study on the bioequivalence of 3,4-diaminopyridine base and 3,4-diaminopyridine salt. Fundam Clin Pharmacol 19:220
14. Deutscher arzneimittel-codex. Deutscher Apotheker Verlag, Stuttgart (2003)
15. IR Edwards C Biriell 1994 Harmonisation in pharmacovigilance Drug Saf 10 93 102 10.2165/00002018-199410020-00001 1:STN:280:DyaK2c3otVKnsw%3D%3D 8011183 (Pubitemid 24045719)
16. EMEA Committee for Orphan Medicinal Products (2003) Public summary of positive opinion for orphan designation of 3,4-diaminopyridine phosphate for the treatment of Lambert-Eaton myasthenic syndrome. London, 29 Jan. EMEA/COMP/2732/02
17. Jost WH, Mielke U, Forrett-Kaminsky MC, Schimrigk K (1992) Long-term treatment of Lambert-Eaton syndrome by 3,4-diaminopyridine. Rev Neurol (Paris) 148:776-779 (Pubitemid 23010967)
18. SI Judge CT Bever 2006 Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment Pharmacol Ther 111 224 259 10.1016/j.pharmthera.2005.10.006 1:CAS:528:DC%2BD28XltVekt74%3D 16472864 (Pubitemid 43765538)
19. Kanzato N, Motomura M, Suehara M, Arimura K (1999) Lambert-Eaton myasthenic syndrome with ophtalmoparesis and pseudoblepharospasm. Muscle Nerve 22:1727-1730
20. D Kos E Kerckhofs G Nagels MB D'hooghe S Ilsbroukx 2008 Origin of fatigue in multiple sclerosis: review of the literature Neurorehabil Neural Repair 22 91 100 1:STN:280:DC%2BD2sjjsFWrsQ%3D%3D 17409388 (Pubitemid 350223141)
21. P Lechat G Deysson M Lemeignan, et al.. 1968 Comparison of acute toxicity of some aminopyridines in vivo (mice) and in vitro (tissue culture) Ann Pharm Fr 26 345 349 1:CAS:528:DyaF1cXks1Gqtb4%3D 5716404
22. D Lorenz K Hagen M Ufer I Cascorbi G Deuschl J Volkmann 2006 No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study Neurology 66 1753 1755 10.1212/01.wnl.0000218297.90054.28 1:CAS:528: DC%2BD28Xksl2hs7Y%3D 16769957 (Pubitemid 43964639)
23. H Lundh O Nilsson I Rosén S Johansson 1993 Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome Acta Neurol Scand 88 136 140 1:STN:280:DyaK2c%2Fis1WktA%3D%3D 8213058 (Pubitemid 23247977)
24. KM McEvoy AJ Windebank JR Dauber PA Low 1989 3,4-diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome N Engl J Med 321 1567 1571 1:STN:280:DyaK3c%2Fms1GqtQ%3D%3D 2555713 (Pubitemid 20008235)
25. Murray NMF, Newsom-Davis J, Karni Y, Wiles CM (1984) Oral 3,4-diaminopyridine in the treatment of the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 47:1052-1053 (Pubitemid 14127311)
26. J Newsom-Davis NM Murray 1984 Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome Neurology 34 480 485 1:STN:280:DyaL2c7kt1KrsQ%3D%3D 6322050 (Pubitemid 14127311)
27. Palace J, Wiles CM, Newsom-Davis J (1991) 3,4-diaminopyridine in the treatment of congenital (hereditary) myasthenia. J Neurol Neurosurg Psychiatry 54:1069-1072
28. A Pelufo-Pellicer E Monte-Boquet E Roma-Sanchez C Casanova-Sorni JL Poveda-Andres 2006 Fetal exposure to 3,4-diaminopyridine in a pregnant woman with congenital myasthenia syndrome Ann Pharmacother 40 762 766 10.1345/aph.1G166 16537815
29. CH Polman FW Bertelsmann R de Waal HA van Diemen BM Uitdehaag AC van Loenen JC Koetsier 1994 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis Arch Neurol 51 1136 1139 1:STN:280:DyaK2M%2FntV2itA%3D%3D 7980110 (Pubitemid 24352857)
30. DB Sanders 1998 3,4-diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS) Ann N Y Acad Sci 841 811 816 10.1111/j.1749-6632.1998.tb11022.x 1:CAS:528:DyaK1cXkslOlsrc%3D 9668334 (Pubitemid 28362942)
31. DB Sanders JF Howard JM Massey 1993 3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis Ann N Y Acad Sci 681 588 590 10.1111/j.1749-6632.1993.tb22949.x 1:STN:280:DyaK3szmt12nsw%3D%3D 8357206 (Pubitemid 23233886)
32. DB Sanders JM Massey LL Sanders LJ Edwards 2000 A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome Neurology 54 603 607 1:CAS:528:DC%2BD3cXht1aktLs%3D 10680790 (Pubitemid 30082925)
33. EW Schafer WA Bocules J Hurlbut 1983 The acute oral toxicity and hazard potential of 998 chemicals to one or more species of wild and domestic birds Arch Environ Contam Toxicol 12 355 382 10.1007/BF01059413 1:CAS:528: DyaL3sXks1Gmsbk%3D 6882015 (Pubitemid 13100406)
34. GL Sheean NM Murray JC Rothwell DH Miller AJ Thompson 1998 An open-labelled clinical and electrophysiological study of 3,4-diaminopyridine in the treatment of fatigue in multiple sclerosis Brain 121 967 975 10.1093/brain/121.5.967 9619197 (Pubitemid 28220901)
35. Solari A, Uitdehaag B, Giuliani G, Pucci E, Taus C (2003) Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane database syst rev 2,CD001330 (Pubitemid 36994996)
36. J Spatt R Chaix B Mamoli 2001 Epileptic and non-epileptic seizures in multiple sclerosis J Neurol 248 2 9 10.1007/s004150170262 1:STN:280: DC%2BD3M7msVCksA%3D%3D 11266015 (Pubitemid 32245438)
37. M Strupp O Schuler S Krafczyk K Jahn F Schautzer U Battner T Brandt 2003 Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study Neurology 61 165 170 1:CAS:528:DC%2BD3sXltVGqsbc%3D 12874393 (Pubitemid 36875295)
38. MM Vohra SN Pradhan 1964 Pharmacology of 3,4-diaminopyridine Arch Int Pharmacodyn Ther 150 413 424 1:CAS:528:DyaF2cXkvVOit7c%3D 14203118
39. M Vohra SN Pradhan PC Jain, et al.. 1965 Synthesis and structure-activity relationships of some aminopyridines, imidazopyridines, and triazolopyridines J Med Chem 17 296 304 10.1021/jm00327a006